{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:48:30Z","timestamp":1790419710717,"version":"4.1.0"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,5,15]],"date-time":"2018-05-15T00:00:00Z","timestamp":1526342400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s40265-018-0920-8","type":"journal-article","created":{"date-parts":[[2018,5,15]],"date-time":"2018-05-15T00:08:10Z","timestamp":1526342890000},"page":"809-821","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Review"],"prefix":"10.1007","volume":"78","author":[{"given":"Lo\u00efc","family":"Raffray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6463-2160","authenticated-orcid":false,"given":"Lo\u00efc","family":"Guillevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,15]]},"reference":[{"key":"920_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65:1\u201311.","journal-title":"Arthritis Rheum."},{"key":"920_CR2","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1002\/art.21250","volume":"52","author":"RA Sinico","year":"2005","unstructured":"Sinico RA, Di Toma L, Maggiore U, Bottero P, Radice A, Tosoni C, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum. 2005;52:2926\u201335.","journal-title":"Arthritis Rheum."},{"key":"920_CR3","doi-asserted-by":"publisher","first-page":"632","DOI":"10.7326\/0003-4819-143-9-200511010-00006","volume":"143","author":"R Sabl\u00e9-Fourtassou","year":"2005","unstructured":"Sabl\u00e9-Fourtassou R, Cohen P, Mahr A, Pagnoux C, Mouthon L, Jayne D, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med. 2005;143:632\u20138.","journal-title":"Ann Intern Med."},{"key":"920_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/00005792-199901000-00003","volume":"78","author":"L Guillevin","year":"1999","unstructured":"Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome: clinical study and long-term follow-up of 96 patients. Medicine (Baltimore). 1999;78:26\u201337.","journal-title":"Medicine (Baltimore)."},{"key":"920_CR5","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/art.37721","volume":"65","author":"C Comarmond","year":"2013","unstructured":"Comarmond C, Pagnoux C, Khellaf M, Cordier J-F, Hamidou M, Viallard J-F, et al. Eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum. 2013;65:270\u201381.","journal-title":"Arthritis Rheum."},{"key":"920_CR6","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/BF01947911","volume":"246","author":"F Wohlwill","year":"1923","unstructured":"Wohlwill F. \u00dcber die nur mikroskopisch erkennbare Form der Periarteriitis nodosa. Virchows Arch Path Anat. 1923;246:377\u2013411.","journal-title":"Virchows Arch Path Anat."},{"key":"920_CR7","first-page":"202","volume":"29","author":"F Wegener","year":"1936","unstructured":"Wegener F. \u00dcber generalisierte, septische Gef\u00e4sserkrankungen. Verhandlungen der Deutschen Pathologischen Gesselschaft. 1936;29:202\u201310.","journal-title":"Verhandlungen der Deutschen Pathologischen Gesselschaft."},{"key":"920_CR8","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1002\/art.1780330806","volume":"33","author":"AT Masi","year":"1990","unstructured":"Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33:1094\u2013100.","journal-title":"Arthritis Rheum."},{"key":"920_CR9","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1056\/NEJMoa1108735","volume":"367","author":"PA Lyons","year":"2012","unstructured":"Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DRW, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 2012;367:214\u201323.","journal-title":"N Engl J Med."},{"key":"920_CR10","unstructured":"Smith K. Genetic studies in ANCA-associated vasculitis point to a new, practical disease classification based on autoantibody specificity. Presented at the 18th International Vasculitis and ANCA Workshop, Tokyo, Japan. Rheumatology (Oxford). 2017;56(Suppl. S3):iii3\u20134."},{"issue":"Suppl. 1","key":"920_CR11","doi-asserted-by":"publisher","first-page":"i14","DOI":"10.1093\/ndt\/gfv022","volume":"30","author":"RA Watts","year":"2015","unstructured":"Watts RA, Mahr A, Mohammad AJ, Gatenby P, Basu N, Flores-Su\u00e1rez LF. Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Nephrol Dial Transplant. 2015;30(Suppl. 1):i14\u201322.","journal-title":"Nephrol Dial Transplant."},{"key":"920_CR12","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1136\/ard.60.12.1156a","volume":"60","author":"RA Watts","year":"2001","unstructured":"Watts RA, Lane SE, Scott DG, Koldingsnes W, Nossent H, Gonzalez-Gay MA, et al. Epidemiology of vasculitis in Europe. Ann Rheum Dis. 2001;60:1156\u20137.","journal-title":"Ann Rheum Dis."},{"key":"920_CR13","doi-asserted-by":"crossref","unstructured":"Watts RA, Scott DGI, Lane SE. Epidemiology of Wegener\u2019s granulomatosis, microscopic polyangiitis, and Churg\u2013Strauss syndrome. Cleve Clin J Med. 2002;69(Suppl. 2):SII84\u20136.","DOI":"10.3949\/ccjm.69.Suppl_2.SII84"},{"key":"920_CR14","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1093\/rheumatology\/kep057","volume":"48","author":"PM Stassen","year":"2009","unstructured":"Stassen PM, Cohen-Tervaert JW, Lems SPM, Hepkema BG, Kallenberg CGM, Stegeman CA. HLA-DR4, DR13(6) and the ancestral haplotype A1B8DR3 are associated with ANCA-associated vasculitis and Wegener\u2019s granulomatosis. Rheumatology (Oxford). 2009;48:622\u20135.","journal-title":"Rheumatology (Oxford)."},{"key":"920_CR15","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1002\/art.22834","volume":"56","author":"A Vaglio","year":"2007","unstructured":"Vaglio A, Martorana D, Maggiore U, Grasselli C, Zanetti A, Pesci A, et al. HLA-DRB4 as a genetic risk factor for Churg-Strauss syndrome. Arthritis Rheum. 2007;56:3159\u201366.","journal-title":"Arthritis Rheum."},{"key":"920_CR16","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/art.23209","volume":"58","author":"S Wieczorek","year":"2008","unstructured":"Wieczorek S, Hellmich B, Gross WL, Epplen JT, et al. Associations of Churg-Strauss syndrome with the HLA-DRB1 locus, and relationship to the genetics of antineutrophil cytoplasmic antibody-associated vasculitides: comment on the article by Vaglio. Arthritis Rheum. 2008;58:329\u201330.","journal-title":"Arthritis Rheum."},{"key":"920_CR17","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1002\/art.23496","volume":"58","author":"S Wieczorek","year":"2008","unstructured":"Wieczorek S, Hellmich B, Arning L, Moosig F, Lamprecht P, Gross WL, et al. Functionally relevant variations of the interleukin-10 gene associated with antineutrophil cytoplasmic antibody-negative Churg-Strauss syndrome, but not with Wegener\u2019s granulomatosis. Arthritis Rheum. 2008;58:1839\u201348.","journal-title":"Arthritis Rheum."},{"key":"920_CR18","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1111\/j.1398-9995.2007.01486.x","volume":"62","author":"P Bottero","year":"2007","unstructured":"Bottero P, Bonini M, Vecchio F, Grittini A, Patruno GM, Colombo B, et al. The common allergens in the Churg-Strauss syndrome. Allergy. 2007;62:1288\u201394.","journal-title":"Allergy."},{"key":"920_CR19","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1001\/jama.279.6.455","volume":"279","author":"ME Wechsler","year":"1998","unstructured":"Wechsler ME, Garpestad E, Flier SR, Kocher O, Weiland DA, Polito AJ, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA. 1998;279:455\u20137.","journal-title":"JAMA."},{"key":"920_CR20","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1136\/thx.2007.087825","volume":"63","author":"T Hauser","year":"2008","unstructured":"Hauser T, Mahr A, Metzler C, Coste J, Sommerstein R, Gross WL, et al. The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study. Thorax. 2008;63:677\u201382.","journal-title":"Thorax."},{"key":"920_CR21","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/1529-0131(200102)44:2<469::AID-ANR66>3.0.CO;2-0","volume":"44","author":"M Kiene","year":"2001","unstructured":"Kiene M, Csernok E, M\u00fcller A, Metzler C, Trabandt A, Gross WL. Elevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg-Strauss syndrome. Arthritis Rheum. 2001;44:469\u201373.","journal-title":"Arthritis Rheum."},{"key":"920_CR22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1196\/annals.1361.053","volume":"1051","author":"B Hellmich","year":"2005","unstructured":"Hellmich B, Csernok E, Gross WL. Proinflammatory cytokines and autoimmunity in Churg-Strauss syndrome. Ann N Y Acad Sci. 2005;1051:121\u201331.","journal-title":"Ann N Y Acad Sci."},{"key":"920_CR23","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1093\/rheumatology\/kes171","volume":"51","author":"B Jakiela","year":"2012","unstructured":"Jakiela B, Szczeklik W, Plutecka H, Sokolowska B, Mastalerz L, Sanak M, et al. Increased production of IL-5 and dominant Th2-type response in airways of Churg-Strauss syndrome patients. Rheumatology (Oxford). 2012;51:1887\u201393.","journal-title":"Rheumatology (Oxford)."},{"issue":"1 Suppl. 64","key":"920_CR24","first-page":"S57","volume":"29","author":"U Fagin","year":"2011","unstructured":"Fagin U, Csernok E, M\u00fcller A, Pitann S, Fazio J, Krause K, et al. Distinct proteinase 3-induced cytokine patterns in Wegener\u2019s granulomatosis, Churg-Strauss syndrome, and healthy controls. Clin Exp Rheumatol. 2011;29(1 Suppl. 64):S57\u201362.","journal-title":"Clin Exp Rheumatol."},{"issue":"1 Suppl. 64","key":"920_CR25","first-page":"S23","volume":"29","author":"B Jakiela","year":"2011","unstructured":"Jakiela B, Sanak M, Szczeklik W, Sokolowska B, Plutecka H, Mastalerz L, et al. Both Th2 and Th17 responses are involved in the pathogenesis of Churg-Strauss syndrome. Clin Exp Rheumatol. 2011;29(1 Suppl. 64):S23\u201334.","journal-title":"Clin Exp Rheumatol."},{"key":"920_CR26","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.3389\/fimmu.2017.01422","volume":"8","author":"C Symowski","year":"2017","unstructured":"Symowski C, Voehringer D. Interactions between innate lymphoid cells and cells of the innate and adaptive immune system. Front Immunol. 2017;8:1422.","journal-title":"Front Immunol."},{"key":"920_CR27","doi-asserted-by":"publisher","first-page":"4523","DOI":"10.1182\/blood-2010-02-267542","volume":"116","author":"B Terrier","year":"2010","unstructured":"Terrier B, Bi\u00e8che I, Maisonobe T, Laurendeau I, Rosenzwajg M, Kahn J-E, et al. Interleukin-25: a cytokine linking eosinophils and adaptive immunity in Churg-Strauss syndrome. Blood. 2010;116:4523\u201331.","journal-title":"Blood."},{"key":"920_CR28","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s10875-013-9898-x","volume":"33","author":"N Tsurikisawa","year":"2013","unstructured":"Tsurikisawa N, Saito H, Oshikata C, Tsuburai T, Akiyama K. Decreases in the numbers of peripheral blood regulatory T cells, and increases in the levels of memory and activated B cells, in patients with active eosinophilic granulomatosis and polyangiitis. J Clin Immunol. 2013;33:965\u201376.","journal-title":"J Clin Immunol."},{"key":"920_CR29","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1002\/art.27678","volume":"62","author":"T Dallos","year":"2010","unstructured":"Dallos T, Heiland GR, Strehl J, Karonitsch T, Gross WL, Moosig F, et al. CCL17\/thymus and activation-related chemokine in Churg-Strauss syndrome. Arthritis Rheum. 2010;62:3496\u2013503.","journal-title":"Arthritis Rheum."},{"key":"920_CR30","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1093\/rheumatology\/keq445","volume":"50","author":"J Zwerina","year":"2011","unstructured":"Zwerina J, Bach C, Martorana D, Jatzwauk M, Hegasy G, Moosig F, et al. Eotaxin-3 in Churg-Strauss syndrome: a clinical and immunogenetic study. Rheumatology (Oxford). 2011;50:1823\u20137.","journal-title":"Rheumatology (Oxford)."},{"key":"920_CR31","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/nrrheum.2014.98","volume":"10","author":"P Khoury","year":"2014","unstructured":"Khoury P, Grayson PC, Klion AD. Eosinophils in vasculitis: characteristics and roles in pathogenesis. Nat Rev Rheumatol. 2014;10:474\u201383.","journal-title":"Nat Rev Rheumatol."},{"key":"920_CR32","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1111\/j.1398-9995.2012.02873.x","volume":"67","author":"P Khoury","year":"2012","unstructured":"Khoury P, Zagallo P, Talar-Williams C, Santos CS, Dinerman E, Holland NC, et al. Serum biomarkers are similar in Churg-Strauss syndrome and hypereosinophilic syndrome. Allergy. 2012;67:1149\u201356.","journal-title":"Allergy."},{"key":"920_CR33","doi-asserted-by":"publisher","first-page":"e0121737","DOI":"10.1371\/journal.pone.0121737","volume":"10","author":"C Dejaco","year":"2015","unstructured":"Dejaco C, Oppl B, Monach P, Cuthbertson D, Carette S, Hoffman G, et al. Serum biomarkers in patients with relapsing eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss). PLoS One. 2015;10:e0121737.","journal-title":"PLoS One."},{"issue":"Suppl. 1","key":"920_CR34","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000210656","volume":"149","author":"H Saito","year":"2009","unstructured":"Saito H, Tsurikisawa N, Tsuburai T, Oshikata C, Akiyama K. Cytokine production profile of CD4+ T cells from patients with active Churg-Strauss syndrome tends toward Th17. Int Arch Allergy Immunol. 2009;149(Suppl. 1):61\u20135.","journal-title":"Int Arch Allergy Immunol."},{"key":"920_CR35","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/BOR.0b013e3282f16c0a","volume":"20","author":"JC Jennette","year":"2008","unstructured":"Jennette JC, Falk RJ. New insight into the pathogenesis of vasculitis associated with antineutrophil cytoplasmic autoantibodies. Curr Opin Rheumatol. 2008;20:55\u201360.","journal-title":"Curr Opin Rheumatol."},{"key":"920_CR36","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1159\/000236817","volume":"105","author":"S Sullivan","year":"1994","unstructured":"Sullivan S, Salapow MA, Breen R, Broide DH. Eosinophil peroxidase differs from neutrophil myeloperoxidase in its ability to bind antineutrophil cytoplasmic antibodies reactive with myeloperoxidase. Int Arch Allergy Immunol. 1994;105:150\u20134.","journal-title":"Int Arch Allergy Immunol."},{"key":"920_CR37","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1136\/annrheumdis-2012-201531","volume":"72","author":"F Moosig","year":"2013","unstructured":"Moosig F, Bremer JP, Hellmich B, Holle JU, Holl-Ulrich K, Laudien M, et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg\u2013Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis. 2013;72:1011\u20137.","journal-title":"Ann Rheum Dis."},{"key":"920_CR38","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/00005792-198403000-00001","volume":"63","author":"JG Lanham","year":"1984","unstructured":"Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore). 1984;63:65\u201381.","journal-title":"Medicine (Baltimore)."},{"key":"920_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.autrev.2016.09.018","volume":"16","author":"V Cottin","year":"2017","unstructured":"Cottin V, Bel E, Bottero P, Dalhoff K, Humbert M, Lazor R, et al. Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss): a study of 157 patients by the Groupe d\u2019Etudes et de Recherche sur les Maladies Orphelines Pulmonaires and the European Respiratory Society Taskforce on Eosinophilic Granulomatosis with Polyangiitis (Churg\u2013Strauss). Autoimmun Rev. 2017;16:1\u20139.","journal-title":"Autoimmun Rev."},{"key":"920_CR40","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nrrheum.2017.140","volume":"13","author":"X Bossuyt","year":"2017","unstructured":"Bossuyt X, Cohen Tervaert J-W, Arimura Y, Blockmans D, Flores-Su\u00e1rez LF, Guillevin L, et al. Position paper: revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol. 2017;13:683\u201392.","journal-title":"Nat Rev Rheumatol."},{"key":"920_CR41","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jaut.2014.01.018","volume":"48\u201349","author":"L Mouthon","year":"2014","unstructured":"Mouthon L, Dunogue B, Guillevin L. Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named Churg-Strauss syndrome). J Autoimmun. 2014;48\u201349:99\u2013103.","journal-title":"J Autoimmun."},{"key":"920_CR42","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1093\/rheumatology\/keu427","volume":"54","author":"PC Grayson","year":"2015","unstructured":"Grayson PC, Monach PA, Pagnoux C, Cuthbertson D, Carette S, Hoffman GS, et al. Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis. Rheumatology (Oxford). 2015;54:1351\u20139.","journal-title":"Rheumatology (Oxford)."},{"key":"920_CR43","first-page":"277","volume":"27","author":"J Churg","year":"1951","unstructured":"Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol. 1951;27:277\u2013301.","journal-title":"Am J Pathol."},{"key":"920_CR44","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ejim.2015.04.022","volume":"26","author":"M Groh","year":"2015","unstructured":"Groh M, Pagnoux C, Baldini C, Bel E, Bottero P, Cottin V, et al. Eosinophilic Granulomatosis with Polyangiitis (Churg\u2013Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med. 2015;26:545\u201353.","journal-title":"Eur J Intern Med."},{"key":"920_CR45","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/00005792-199601000-00003","volume":"75","author":"L Guillevin","year":"1996","unstructured":"Guillevin L, Lhote F, Gayraud M, Cohen P, Jarrousse B, Lortholary O, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome: a prospective study in 342 patients. Medicine (Baltimore). 1996;75:17\u201328.","journal-title":"Medicine (Baltimore)."},{"key":"920_CR46","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/MD.0b013e318205a4c6","volume":"90","author":"L Guillevin","year":"2011","unstructured":"Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin P, et al. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine (Baltimore). 2011;90:19\u201327.","journal-title":"Medicine (Baltimore)."},{"key":"920_CR47","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaut.2013.03.003","volume":"43","author":"M Samson","year":"2013","unstructured":"Samson M, Pu\u00e9chal X, Devilliers H, Ribi C, Cohen P, Stern M, et al. Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss syndrome) enrolled in two prospective trials. J Autoimmun. 2013;43:60\u20139.","journal-title":"J Autoimmun."},{"key":"920_CR48","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/art.22679","volume":"57","author":"P Cohen","year":"2007","unstructured":"Cohen P, Pagnoux C, Mahr A, Ar\u00e8ne J-P, Mouthon L, Le Guern V, et al. Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum. 2007;57:686\u201393.","journal-title":"Arthritis Rheum."},{"key":"920_CR49","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/art.23198","volume":"58","author":"C Ribi","year":"2008","unstructured":"Ribi C, Cohen P, Pagnoux C, Mahr A, Ar\u00e8ne J-P, Lauque D, et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum. 2008;58:586\u201394.","journal-title":"Arthritis Rheum."},{"key":"920_CR50","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","volume":"75","author":"M Yates","year":"2016","unstructured":"Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, et al. EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75:1583\u201394.","journal-title":"Ann Rheum Dis."},{"key":"920_CR51","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1002\/art.40205","volume":"69","author":"X Pu\u00e9chal","year":"2017","unstructured":"Pu\u00e9chal X, Pagnoux C, Baron G, Qu\u00e9meneur T, N\u00e9el A, Agard C, et al. Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss), microscopic polyangiitis, or polyarteritis nodosa without poor prognosis factors: a randomized, controlled trial. Arthritis Rheumatol. 2017;69:2175\u201386.","journal-title":"Arthritis Rheumatol."},{"key":"920_CR52","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","volume":"376","author":"ME Wechsler","year":"2017","unstructured":"Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376:1921\u201332.","journal-title":"N Engl J Med."},{"key":"920_CR53","doi-asserted-by":"publisher","first-page":"341","DOI":"10.7326\/0003-4819-155-5-201109060-00026","volume":"155","author":"F Moosig","year":"2011","unstructured":"Moosig F, Gross WL, Herrmann K, Bremer JP, Hellmich B. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann Intern Med. 2011;155:341\u20133.","journal-title":"Ann Intern Med."},{"key":"920_CR54","unstructured":"US National Library of Medicine. Rituximab in eosinophilic granulomatosis with polyangiitis. ClinicalTrials.gov identifier: NCT02807103. \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02807103\n                    \n                  . Accessed 20 Dec 2017."},{"key":"920_CR55","unstructured":"US National Library of Medicine. Maintenance of remission with rituximab versus azathioprine for newly-diagnosed or relapsing eosinophilic granulomatosis with polyangiitis. ClinicalTrials.gov identifier: NCT03164473. \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03164473\n                    \n                  . Accessed 20 Dec 2017."},{"key":"920_CR56","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221\u201332.","journal-title":"N Engl J Med."},{"key":"920_CR57","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1213277","volume":"369","author":"U Specks","year":"2013","unstructured":"Specks U, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013;369:417\u201327.","journal-title":"N Engl J Med."},{"key":"920_CR58","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","volume":"371","author":"L Guillevin","year":"2014","unstructured":"Guillevin L, Pagnoux C, Karras A, Khouatra C, Auma\u00eetre O, Cohen P, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371:1771\u201380.","journal-title":"N Engl J Med."},{"key":"920_CR59","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","volume":"359","author":"C Pagnoux","year":"2008","unstructured":"Pagnoux C, Mahr A, Hamidou MA, Boffa J-J, Ruivard M, Ducroix J-P, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359:2790\u2013803.","journal-title":"N Engl J Med."},{"key":"920_CR60","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1001\/jama.2010.1658","volume":"304","author":"TF Hiemstra","year":"2010","unstructured":"Hiemstra TF, Walsh M, Mahr A, Savage CO, de Groot K, Harper L, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA. 2010;304:2381\u20138.","journal-title":"JAMA."},{"key":"920_CR61","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1681\/ASN.2007010090","volume":"18","author":"DRW Jayne","year":"2007","unstructured":"Jayne DRW, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18:2180\u20138.","journal-title":"J Am Soc Nephrol."},{"key":"920_CR62","unstructured":"US National Library of Medicine. Plasma exchange and glucocorticoids for treatment of anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (PEXIVAS). ClinicalTrials.gov identifier: NCT00987389. \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00987389\n                    \n                  . Accessed 12 Jan 2018."},{"issue":"1 Suppl. 70","key":"920_CR63","first-page":"S77","volume":"30","author":"A Kostianovsky","year":"2012","unstructured":"Kostianovsky A, Hauser T, Pagnoux C, Cohen P, Daugas E, Mouthon L, et al. Alveolar haemorrhage in ANCA-associated vasculitides: 80 patients\u2019 features and prognostic factors. Clin Exp Rheumatol. 2012;30(1 Suppl. 70):S77\u201382.","journal-title":"Clin Exp Rheumatol."},{"key":"920_CR64","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/art.23147","volume":"58","author":"V Martinez","year":"2008","unstructured":"Martinez V, Cohen P, Pagnoux C, Vinzio S, Mahr A, Mouthon L, et al. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum. 2008;58:308\u201317.","journal-title":"Arthritis Rheum."},{"key":"920_CR65","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/qjmed\/93.7.433","volume":"93","author":"DR Jayne","year":"2000","unstructured":"Jayne DR, Chapel H, Adu D, Misbah S, O\u2019Donoghue D, Scott D, et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM. 2000;93:433\u20139.","journal-title":"QJM."},{"key":"920_CR66","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1093\/rheumatology\/35.11.1150","volume":"35","author":"DR Jayne","year":"1996","unstructured":"Jayne DR, Lockwood CM. Intravenous immunoglobulin as sole therapy for systemic vasculitis. Br J Rheumatol. 1996;35:1150\u20133.","journal-title":"Br J Rheumatol."},{"key":"920_CR67","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1146\/annurev-med-070912-133235","volume":"65","author":"M Faurschou","year":"2014","unstructured":"Faurschou M, Jayne DRW. Anti-B cell antibody therapies for inflammatory rheumatic diseases. Annu Rev Med. 2014;65:263\u201378.","journal-title":"Annu Rev Med."},{"key":"920_CR68","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones RB, Tervaert JWC, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363:211\u201320.","journal-title":"N Engl J Med."},{"key":"920_CR69","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1093\/rheumatology\/ket381","volume":"53","author":"P Charles","year":"2014","unstructured":"Charles P, N\u00e9el A, Tieuli\u00e9 N, Hot A, Pugnet G, Decaux O, et al. Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients. Rheumatology (Oxford). 2014;53:532\u20139.","journal-title":"Rheumatology (Oxford)."},{"key":"920_CR70","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/ard.2005.042937","volume":"65","author":"M Koukoulaki","year":"2006","unstructured":"Koukoulaki M, Smith KGC, Jayne DRW. Rituximab in Churg-Strauss syndrome. Ann Rheum Dis. 2006;65:557\u20139.","journal-title":"Ann Rheum Dis."},{"key":"920_CR71","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1093\/rheumatology\/ken175","volume":"47","author":"RJ Pepper","year":"2008","unstructured":"Pepper RJ, Fabre MA, Pavesio C, Gaskin G, Jones RB, Jayne D, et al. Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology (Oxford). 2008;47:1104\u20135.","journal-title":"Rheumatology (Oxford)."},{"key":"920_CR72","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1136\/ard.2008.093773","volume":"68","author":"M-A Bouldouyre","year":"2009","unstructured":"Bouldouyre M-A, Cohen P, Guillevin L. Severe bronchospasm associated with rituximab for refractory Churg-Strauss syndrome. Ann Rheum Dis. 2009;68:606.","journal-title":"Ann Rheum Dis."},{"key":"920_CR73","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00296-009-1146-6","volume":"31","author":"KK D\u00f8nvik","year":"2011","unstructured":"D\u00f8nvik KK, Omdal R. Churg-Strauss syndrome successfully treated with rituximab. Rheumatol Int. 2011;31:89\u201391.","journal-title":"Rheumatol Int."},{"key":"920_CR74","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1093\/ndt\/gfq852","volume":"26","author":"R Cartin-Ceba","year":"2011","unstructured":"Cartin-Ceba R, Keogh KA, Specks U, Sethi S, Fervenza FC. Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. Nephrol Dial Transplant. 2011;26:2865\u201371.","journal-title":"Nephrol Dial Transplant."},{"key":"920_CR75","doi-asserted-by":"publisher","first-page":"R133","DOI":"10.1186\/ar4313","volume":"15","author":"J Thiel","year":"2013","unstructured":"Thiel J, H\u00e4ssler F, Salzer U, Voll RE, Venhoff N. Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss syndrome). Arthritis Res Ther. 2013;15:R133.","journal-title":"Arthritis Res Ther."},{"key":"920_CR76","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jbspin.2015.04.016","volume":"83","author":"P Novikov","year":"2016","unstructured":"Novikov P, Moiseev S, Smitienko I, Zagvozdkina E. Rituximab as induction therapy in relapsing eosinophilic granulomatosis with polyangiitis: a report of 6 cases. Joint Bone Spine. 2016;83:81\u20134.","journal-title":"Joint Bone Spine."},{"key":"920_CR77","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1136\/annrheumdis-2014-206095","volume":"75","author":"AJ Mohammad","year":"2016","unstructured":"Mohammad AJ, Hot A, Arndt F, Moosig F, Guerry M-J, Amudala N, et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss). Ann Rheum Dis. 2016;75:396\u2013401.","journal-title":"Ann Rheum Dis."},{"key":"920_CR78","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1016\/j.jaip.2017.07.027","volume":"5","author":"J Thiel","year":"2017","unstructured":"Thiel J, Troilo A, Salzer U, Schleyer T, Halmschlag K, Rizzi M, et al. Rituximab as induction therapy in eosinophilic granulomatosis with polyangiitis refractory to conventional immunosuppressive treatment: a 36-month follow-up analysis. J Allergy Clin Immunol Pract. 2017;5:1556\u201363.","journal-title":"J Allergy Clin Immunol Pract."},{"key":"920_CR79","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cyto.2016.11.011","volume":"98","author":"T Yanagibashi","year":"2017","unstructured":"Yanagibashi T, Satoh M, Nagai Y, Koike M, Takatsu K. Allergic diseases: from bench to clinic-contribution of the discovery of interleukin-5. Cytokine. 2017;98:59\u201370.","journal-title":"Cytokine."},{"key":"920_CR80","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1016\/S0140-6736(00)03496-6","volume":"356","author":"MJ Leckie","year":"2000","unstructured":"Leckie MJ, ten Brinke A, Khan J, Diamant Z, O\u2019Connor BJ, Walls CM, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000;356:2144\u20138.","journal-title":"Lancet."},{"key":"920_CR81","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1007\/s40265-015-0513-8","volume":"75","author":"GM Keating","year":"2015","unstructured":"Keating GM. Mepolizumab: first global approval. Drugs. 2015;75:2163\u20139.","journal-title":"Drugs."},{"key":"920_CR82","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","volume":"371","author":"HG Ortega","year":"2014","unstructured":"Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198\u2013207.","journal-title":"N Engl J Med."},{"key":"920_CR83","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","volume":"371","author":"EH Bel","year":"2014","unstructured":"Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189\u201397.","journal-title":"N Engl J Med."},{"key":"920_CR84","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","volume":"380","author":"ID Pavord","year":"2012","unstructured":"Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651\u20139.","journal-title":"Lancet."},{"key":"920_CR85","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jaci.2009.10.014","volume":"125","author":"J-E Kahn","year":"2010","unstructured":"Kahn J-E, Grandpeix-Guyodo C, Marroun I, Catherinot E, Mellot F, Roufosse F, et al. Sustained response to mepolizumab in refractory Churg-Strauss syndrome. J Allergy Clin Immunol. 2010;125:267\u201370.","journal-title":"J Allergy Clin Immunol."},{"key":"920_CR86","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.jaci.2010.03.028","volume":"125","author":"S Kim","year":"2010","unstructured":"Kim S, Marigowda G, Oren E, Israel E, Wechsler ME. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol. 2010;125:1336\u201343.","journal-title":"J Allergy Clin Immunol."},{"issue":"1 Suppl. 70","key":"920_CR87","first-page":"S62","volume":"30","author":"K Herrmann","year":"2012","unstructured":"Herrmann K, Gross WL, Moosig F. Extended follow-up after stopping mepolizumab in relapsing\/refractory Churg-Strauss syndrome. Clin Exp Rheumatol. 2012;30(1 Suppl. 70):S62\u20135.","journal-title":"Clin Exp Rheumatol."},{"key":"920_CR88","unstructured":"US National Library of Medicine. Long-term access program (LAP) of mepolizumab for subjects who participated in study MEA115921. ClinicalTrials.gov identifier: NCT03298061. \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03298061\n                    \n                  . Accessed 20 Dec 2017."},{"key":"920_CR89","unstructured":"US National Library of Medicine. Reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) study. ClinicalTrials.gov identifier: NCT02947945. Available from: \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02947945\n                    \n                  . Accessed 20 Dec 2017."},{"key":"920_CR90","unstructured":"US National Library of Medicine. Benralizumab in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) study. ClinicalTrials.gov identifier: NCT03010436. \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03010436\n                    \n                  . Accessed 20 Dec 2017."},{"issue":"2 Suppl. 1","key":"920_CR91","first-page":"S15","volume":"27","author":"S Soresi","year":"2006","unstructured":"Soresi S, Togias A. Mechanisms of action of anti-immunoglobulin E therapy. Allergy Asthma Proc. 2006;27(2 Suppl. 1):S15\u201323.","journal-title":"Allergy Asthma Proc."},{"key":"920_CR92","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s40265-013-0085-4","volume":"73","author":"K McKeage","year":"2013","unstructured":"McKeage K. Omalizumab: a review of its use in patients with severe persistent allergic asthma. Drugs. 2013;73:1197\u2013212.","journal-title":"Drugs."},{"key":"920_CR93","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1007\/s40265-014-0290-9","volume":"74","author":"PL McCormack","year":"2014","unstructured":"McCormack PL. Omalizumab: a review of its use in patients with chronic pontaneous urticaria. Drugs. 2014;74:1693\u20139.","journal-title":"Drugs."},{"key":"920_CR94","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1002\/art.39663","volume":"68","author":"M Jachiet","year":"2016","unstructured":"Jachiet M, Samson M, Cottin V, Kahn J-E, Le Guenno G, Bonniaud P, et al. Anti-IgE monoclonal antibody (omalizumab) in refractory and relapsing eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss): data on seventeen patients. Arthitis Rheumatol. 2016;68:2274\u201382.","journal-title":"Arthitis Rheumatol."},{"key":"920_CR95","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3109\/02770903.2015.1081700","volume":"53","author":"A Detoraki","year":"2016","unstructured":"Detoraki A, Capua LD, Varricchi G, Genovese A, Marone G, Spadaro G. Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study. J Asthma. 2016;53:201\u20136.","journal-title":"J Asthma."},{"key":"920_CR96","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1159\/000103228","volume":"144","author":"P Giavina-Bianchi","year":"2007","unstructured":"Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, Kalil J. Administration of anti-IgE to a Churg-Strauss syndrome patient. Int Arch Allergy Immunol. 2007;144:155\u20138.","journal-title":"Int Arch Allergy Immunol."},{"key":"920_CR97","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1136\/thx.2006.076513","volume":"63","author":"S Pabst","year":"2008","unstructured":"Pabst S, Tiyerili V, Groh\u00e9 C. Apparent response to anti-IgE therapy in two patients with refractory \u201cforme fruste\u201d of Churg-Strauss syndrome. Thorax. 2008;63:747\u20138.","journal-title":"Thorax."},{"key":"920_CR98","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1440-1843.2010.01884.x","volume":"16","author":"EMT Lau","year":"2011","unstructured":"Lau EMT, Cooper W, Bye PT, Yan K. Difficult asthma and Churg\u2013Strauss-like syndrome: a cautionary tale. Respirology. 2011;16:180\u20131.","journal-title":"Respirology."},{"key":"920_CR99","doi-asserted-by":"publisher","first-page":"E78","DOI":"10.1002\/ppul.22884","volume":"49","author":"E Iglesias","year":"2014","unstructured":"Iglesias E, Camacho Lovillo M, Delgado Pecell\u00edn I, Lirola Cruz MJ, Falc\u00f3n Neyra MD, Salazar Quero JC, et al. Successful management of Churg-Strauss syndrome using omalizumab as adjuvant immunomodulatory therapy: first documented pediatric case. Pediatr Pulmonol. 2014;49:E78\u201381.","journal-title":"Pediatr Pulmonol."},{"key":"920_CR100","first-page":"226","volume":"46","author":"A Graziani","year":"2014","unstructured":"Graziani A, Quercia O, Girelli F, Martelli A, Mirici Cappa F, Stefanini GF. Omalizumab treatment in patient with severe asthma and eosinophilic granulomatosis with polyangiitis: a case report. Eur Ann Allergy Clin Immunol. 2014;46:226\u20138.","journal-title":"Eur Ann Allergy Clin Immunol."},{"key":"920_CR101","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1007\/s10067-017-3780-9","volume":"36","author":"D Aguirre-Valencia","year":"2017","unstructured":"Aguirre-Valencia D, Posso-Osorio I, Bravo J-C, Bonilla-Abad\u00eda F, Tob\u00f3n GJ, Ca\u00f1as CA. Sequential rituximab and omalizumab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss syndrome). Clin Rheumatol. 2017;36:2159\u201362.","journal-title":"Clin Rheumatol."},{"key":"920_CR102","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.anai.2016.12.003","volume":"118","author":"S Nazir","year":"2017","unstructured":"Nazir S, Tachamo N, Fareedy SB, Khan MS, Lohani S. Omalizumab-associated eosinophilic granulomatosis with polyangiitis (Churg\u2013Strauss syndrome). Ann Allergy Asthma Immunol. 2017;118:372\u20134.","journal-title":"Ann Allergy Asthma Immunol."},{"key":"920_CR103","doi-asserted-by":"publisher","first-page":"129","DOI":"10.5152\/eurjrheum.2015.0086","volume":"2","author":"M Bek\u00e7iba\u015f\u0131","year":"2015","unstructured":"Bek\u00e7iba\u015f\u0131 M, Barut\u00e7u S, \u00c7elen MK, Dayan S, Ho\u015fo\u011flu S. Churg-Strauss syndrome occurring during omalizumab treatment. Eur J Rheumatol. 2015;2:129\u201330.","journal-title":"Eur J Rheumatol."},{"key":"920_CR104","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/S0221-0363(09)73273-1","volume":"90","author":"D Szwarc","year":"2009","unstructured":"Szwarc D, Veillon F, Moser T, Averous G, De Blay F, Riehm S. Churg-Strauss syndrome under omalizumab treatment: a rare visceral manifestation [in French]. J Radiol. 2009;90:1737\u20139.","journal-title":"J Radiol"},{"key":"920_CR105","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1378\/chest.08-2990","volume":"136","author":"ME Wechsler","year":"2009","unstructured":"Wechsler ME, Wong DA, Miller MK, Lawrence-Miyasaki L. Churg-Strauss syndrome in patients treated with omalizumab. Chest. 2009;136:507\u201318.","journal-title":"Chest."},{"key":"920_CR106","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1172\/JCI118417","volume":"97","author":"L Schanden\u00e9","year":"1996","unstructured":"Schanden\u00e9 L, Del Prete GF, Cogan E, Stordeur P, Crusiaux A, Kennes B, et al. Recombinant interferon-alpha selectively inhibits the production of interleukin-5 by human CD4\u2009+\u2009T cells. J Clin Invest. 1996;97:309\u201315.","journal-title":"J Clin Invest."},{"key":"920_CR107","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jaci.2005.03.016","volume":"116","author":"H Shibuya","year":"2005","unstructured":"Shibuya H, Hirohata S. Differential effects of IFN-alpha on the expression of various TH2 cytokines in human CD4+ T cells. J Allergy Clin Immunol. 2005;116:205\u201312.","journal-title":"J Allergy Clin Immunol."},{"key":"920_CR108","doi-asserted-by":"publisher","first-page":"370","DOI":"10.7326\/0003-4819-129-5-199809010-00004","volume":"129","author":"E Tatsis","year":"1998","unstructured":"Tatsis E, Schnabel A, Gross WL. Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med. 1998;129:370\u20134.","journal-title":"Ann Intern Med."},{"key":"920_CR109","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/S0953-6205(02)00136-X","volume":"13","author":"O Lesens","year":"2002","unstructured":"Lesens O, Hansmann Y, Nerson J, Pasquali J, Gasser B, Wihlm J, et al. Severe Churg-Strauss syndrome with mediastinal lymphadenopathy treated with interferon therapy. Eur J Intern Med. 2002;13:458.","journal-title":"Eur J Intern Med."},{"key":"920_CR110","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1046\/j.1398-9995.2003.00424.x","volume":"58","author":"H-U Simon","year":"2003","unstructured":"Simon H-U, Seelbach H, Ehmann R, Schmitz M. Clinical and immunological effects of low-dose IFN-alpha treatment in patients with corticosteroid-resistant asthma. Allergy. 2003;58:1250\u20135.","journal-title":"Allergy."},{"key":"920_CR111","first-page":"24","volume":"28","author":"C Metzler","year":"2010","unstructured":"Metzler C, Csernok E, Gross WL, Hellmich B. Interferon-alpha for maintenance of remission in Churg-Strauss syndrome: a long-term observational study. Clin Exp Rheumatol. 2010;28:24\u201330.","journal-title":"Clin Exp Rheumatol."},{"key":"920_CR112","doi-asserted-by":"publisher","first-page":"806","DOI":"10.3899\/jrheum.160907","volume":"44","author":"B Seeliger","year":"2017","unstructured":"Seeliger B, F\u00f6rster M, Happe J, Forberg T, Moeser A, Neumann T, et al. Interferon-\u03b1 for induction and maintenance of remission in eosinophilic granulomatosis with polyangiitis: a single-center retrospective observational cohort study. J Rheumatol. 2017;44:806\u201314.","journal-title":"J Rheumatol."},{"key":"920_CR113","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1681\/ASN.2005121359","volume":"17","author":"M Feldmann","year":"2006","unstructured":"Feldmann M, Pusey CD. Is there a role for TNF-alpha in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases. J Am Soc Nephrol. 2006;17:1243\u201352.","journal-title":"J Am Soc Nephrol."},{"key":"920_CR114","doi-asserted-by":"publisher","first-page":"c89","DOI":"10.1159\/000319655","volume":"117","author":"MD Morgan","year":"2011","unstructured":"Morgan MD, Drayson MT, Savage COS, Harper L. Addition of infliximab to standard therapy for ANCA-associated vasculitis. Nephron Clin Pract. 2011;117:c89\u201397.","journal-title":"Nephron Clin Pract."},{"key":"920_CR115","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa041884","volume":"352","author":"Wegener\u2019s Granulomatosis Etanercept Trial","year":"2005","unstructured":"Wegener\u2019s Granulomatosis Etanercept Trial. (WGET) Research Group. Etanercept plus standard therapy for Wegener\u2019s granulomatosis. N Engl J Med. 2005;352:351\u201361.","journal-title":"N Engl J Med."},{"key":"920_CR116","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1078\/0171-2985-00197","volume":"206","author":"O Arbach","year":"2002","unstructured":"Arbach O, Gross WL, Gause A. Treatment of refractory Churg-Strauss syndrome (CSS) by TNF-alpha blockade. Immunobiology. 2002;206:496\u2013501.","journal-title":"Immunobiology."},{"key":"920_CR117","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/01.rhu.0000120897.08819.ac","volume":"10","author":"A Tiliakos","year":"2004","unstructured":"Tiliakos A, Shaia S, Hostoffer R, Kent L. The use of infliximab in a patient with steroid-dependent Churg-Strauss syndrome. J Clin Rheumatol. 2004;10:96\u20137.","journal-title":"J Clin Rheumatol."},{"key":"920_CR118","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1183\/09031936.00202013","volume":"43","author":"KF Chung","year":"2014","unstructured":"Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343\u201373.","journal-title":"Eur Respir J."},{"key":"920_CR119","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1007\/s40265-017-0803-4","volume":"77","author":"DM Beswick","year":"2017","unstructured":"Beswick DM, Gray ST, Smith TL. Pharmacological management of chronic rhinosinusitis: current and evolving treatments. Drugs. 2017;77:1713\u201321.","journal-title":"Drugs."},{"key":"920_CR120","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/BF02714432","volume":"165","author":"L Guillevin","year":"1987","unstructured":"Guillevin L, Guittard T, Bl\u00e9try O, Godeau P, Rosenthal P. Systemic necrotizing angiitis with asthma: causes and precipitating factors in 43 cases. Lung. 1987;165:165\u201372.","journal-title":"Lung."},{"issue":"5","key":"920_CR121","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/annrheumdis-2017-211796","volume":"77","author":"JW Park","year":"2018","unstructured":"Park JW, Curtis JR, Moon J, Song YW, Kim S, Lee EB. Prophylactic effect of trimethoprim-sulfamethoxazole for Pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis. 2018;77(5):644\u20139.","journal-title":"Ann Rheum Dis."},{"key":"920_CR122","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/ar2826","volume":"11","author":"F Moosig","year":"2009","unstructured":"Moosig F, Holle JU, Gross WL. Value of anti-infective chemoprophylaxis in primary systemic vasculitis: what is the evidence? Arthritis Res Ther. 2009;11:253.","journal-title":"Arthritis Res Ther."},{"issue":"Suppl. 103","key":"920_CR123","first-page":"176","volume":"35","author":"M Samson","year":"2017","unstructured":"Samson M, Pu\u00e9chal X, Mouthon L, Devilliers H, Cohen P, Bienvenu B, et al. Microscopic polyangiitis and non-HBV polyarteritis nodosa with poor-prognosis factors: 10-year results of the prospective CHUSPAN trial. Clin Exp Rheumatol. 2017;35(Suppl. 103):176\u201384.","journal-title":"Clin Exp Rheumatol."},{"key":"920_CR124","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s12016-014-8444-9","volume":"50","author":"P Sriaroon","year":"2016","unstructured":"Sriaroon P, Ballow M. Biological modulators in eosinophilic diseases. Clin Rev Allergy Immunol. 2016;50:252\u201372.","journal-title":"Clin Rev Allergy Immunol."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-018-0920-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0920-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0920-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T20:39:33Z","timestamp":1557866373000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-018-0920-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,15]]},"references-count":124,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["920"],"URL":"https:\/\/doi.org\/10.1007\/s40265-018-0920-8","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,15]]},"assertion":[{"value":"15 May 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Lo\u00efc Raffray received financial support for attending symposia from Amgen in 2017 and AbbVie in 2016. Lo\u00efc Guillevin has no conflicts of interest directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}